Richness premium for linked kinds of data
3x3x to 6.67x
times single-source data, at full richness
- How it is computed
- How much more health data linking several kinds (records with scans, genomes or treatment data) sells for than single-source data: the market's price ratios between them. Conservative: the lowest ratio in the market is the typical premium, because the richer tiers (expert-curated records, records with genomes) hold more than a contributor uploads. A contribution earns it in proportion to how many kinds of data it links, in full at 4 (a modelling choice).
- Strength
- Derived: arithmetic on disclosed figures
The evidence (4)
- NHS patient record linked with genomic and phenotypic data against EHR/EMR data alone
EY, How we can place a value on health care data (19 July 2019), 2019-07. Quote found at the source on 2026-11-06.
between £1000–5000 per record when combined with genomic and phenotypic data
- Curated unstructured EHR data licence against claims data licence, per therapeutic area per year (price ladder)
Dagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design, 2021-11. Quote found at the source on 2026-11-06.
$100k–300k per therapeutic area (claims) and $3–5 million per TA (curated EHR)
- Structured EHR data licence against claims data licence, per therapeutic area per year (price ladder)
Dagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design, 2021-11. Quote found at the source on 2026-11-06.
$100k–300k per therapeutic area (claims) and $1–3 million per TA (structured EHR)
- UK Biobank Tier 3 (adds imaging and sequence data) against Tier 1 (questionnaires, measurements, linked health data), first three years
UK Biobank, Fees (read from an Internet Archive copy, 2025; fees exclude VAT), 2025-01. Source re-read on 2026-11-06 needs a browser (PDF or protected page).
£3,000 and £9,000